Navigation Links
Mira Dx Licenses Triple Negative Breast Cancer Risk Variant from Yale University
Date:2/24/2011

NEW HAVEN, Conn., Feb. 24, 2011 /PRNewswire/ -- Mira Dx announced today that it has licensed technology from Yale University based on the acceptance of a pivotal breast cancer study in the January issue of the journal Cell Cycle. While numerous BRCA1 coding sequence mutations are associated with breast cancer risk, such mutations in BRCA1 account for less than 5% of breast cancer risk. The research identified microRNA disrupting variants in and around BRCA1 that are polymorphic in breast cancer populations. One key variant (rs8176318) shows significant cancer association for predicting the risk of developing triple negative breast cancer, especially for African American women.

It is estimated that last year in the US more than 207,090 women were diagnosed with breast cancer, and that 39,840 women died from the disease, according to the National Cancer Institute website. Triple negative breast cancer accounts for 15-20% of all breast cancers, and is the most deadly form of this disease.

"There is a real need for tools that can help women who have a family history of breast cancer to better understand their risk," said Martin Van Verhoef, President & CEO of Mira Dx. "We are pleased to continue our advancements in the field of miRNAs in cancer risk and plan to make this information available to women in 2011 in the form of a new triple negative breast cancer risk test." Verhoef continued, "We hope that cancer risk markers such as this marker will provide valuable information for the tens of thousands of women and families each year who are and may be affected by triple negative breast cancer."

Mira Dx was formed in February 2008 by researchers at Yale University to discover gene-based laboratory tests conducted on newly discovered genetic regulators called microRNAs (miRNAs). Mira Dx is applying miRNA discoveries to develop molecular diagnostics, which will provide individualized information on the likelihood of disease occurrence and response to certain types of therapy.

Mira Dx operates a CLIA lab out of New Haven, CT and currently runs a test to identify women at risk of epithelial ovarian cancer, PreOvar. Information on PreOvar and Mira Dx is available from the company's website, www.MiraDx.com.

About Mira DxMira Dx is a genomics company founded on research discovered at Yale University that is dedicated to the development and commercialization of novel microRNA-based tests for risk assessment and companion diagnostics. Our goal is to provide information that can help clinicians better understand cancer to better serve their patients, allowing earlier diagnosis, better management and ultimately higher cure rates.  For more information, please visit www.MiraDx.com.For more information, contact:Stephen Miller, Mira Dxsmiller@miradx.com, 203-789-9000 x206
'/>"/>

SOURCE Mira Dx
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
2. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
3. Duke Licenses ALPHADAS(R), Logos Technologies EDC System to Accelerate its Early Phase Clinical Trials
4. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
5. Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
6. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
9. PSKW & Associates LLC Acquires Triax Media, Licenses Triax to Subsidiary, Centricity Group
10. TenX Biopharma Licenses Zanolimumab From Genmab
11. Omnicare Clinical Research Licenses LiquentConnect to Create Added Value for Clients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):